Page 1

idogen Idogen AB Interim report January 1 - March 31 , 2021 " During the year , we are looking forward to moving our first cell therapy project into clinical phase a key milestone in our efforts to improve life for a number of patient cohorts , whose current treatments leave much to be desired " Idogen AB ( publ ) Corp. Reg . No .: 556756-8521 www.idogen.com Anders Karlsson , CEO